Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 18/20 | 1.00 |
| ▸ | MMP2 | P08253 | 7/20 | 1.00 |
| ▸ | MMP9 | P14780 | 7/20 | 1.00 |
| ▸ | MMP3 | P08254 | 6/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12336942 | 0.87 | MMP13 (1.00) | MMP13MMP2MMP9MMP3MMP8 | |
| SCHEMBL6731065 | 0.87 | MMP13 (1.00) | MMP13MMP2MMP9MMP3 | |
| SCHEMBL6727168 | 0.81 | MMP13 (0.86) | MMP13MMP2MMP9MMP3MMP8 | |
| SCHEMBL6727173 | 0.81 | MMP13 (0.73) | MMP13MMP2MMP9MMP3 | |
| SCHEMBL6719742 | 0.81 | MMP13 (0.73) | MMP13MMP2MMP9MMP3 | |
| SCHEMBL6727253 | 0.79 | MMP13 (0.76) | MMP13MMP2MMP9MMP3 | |
| SCHEMBL6724553 | 0.77 | MMP13 (1.00) | MMP13MMP2MMP9MMP3 | |
| SCHEMBL6724183 | 0.76 | MMP13 (1.00) | MMP13MMP2MMP9MMP3 | |
| SCHEMBL6727261 | 0.76 | MMP13 (0.67) | MMP13MMP2MMP9MMP3 | |
| SCHEMBL6330450 | 0.76 | MMP13 (0.66) | MMP13MMP2MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024001-A1 | Spirobarbituric acid derivatives useful as inhibitors of matrix metalloproteases | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-05 | — | — | US | claimed |
| WO-2003091252-A1 | SPIROBARBITURIC ACID DERIVATIVES USEFUL AS INHIBITORS OF MATRIX METALLOPROTEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024001-A1 | Spirobarbituric acid derivatives useful as inhibitors of matrix metalloproteases | MMP13, MMP3, MMP1 | MMP13 1/4885MMP2 13/4885MMP9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.